Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
25 03 2020
Historique:
received: 22 01 2020
accepted: 31 01 2020
pubmed: 7 2 2020
medline: 24 6 2021
entrez: 7 2 2020
Statut: epublish

Résumé

Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common condition of employment for health care workers (HCWs) to ensure compliance with national standards and state laws. When documentation of complete vaccination or laboratory-confirmed infection is not available, Advisory Committee on Immunization Practices (ACIP) criteria are used to guide vaccination or anti-MMRV IgG testing. We assessed the performance of the BioPlex 2200 MMRV IgG multiplex flow immunoassay (MFI; Bio-Rad Laboratories, Hercules, CA) and matched immunofluorescence assays (IFAs; MBL Bion, Des Plaines, IL) in 220 HCWs categorized by ACIP criteria for presumptive immunity to MMRV. Among HCWs presumptively immune to measles, mumps, rubella, and VZV, the Bio-Rad MFI was positive in 77.3, 85.4, 84.3, and 91.1% of HCWs, respectively. Comparatively, the Bion IFA was positive in 92.9, 91.1, and 93.5% of HCWs presumptively immune to measles, mumps, and VZV (a rubella IFA was unavailable). Among HCWs fully vaccinated against measles, mumps, and VZV, Bio-Rad MFI/Bion IFA positivity rates were 77.4%/93%, 84.8%/90.7%, and 54.5%/90.9%, respectively. The Bio-Rad MFI was positive in 83.7% of HCWs fully vaccinated against rubella. For HCWs whose last vaccination event occurred within 15 years of enrollment, 83.3, 93.3, and 74.2% were positive by the Bio-Rad measles, mumps, and rubella IgG MFIs, respectively. We show significantly decreased Bio-Rad MFI sensitivity for detection of anti-measles and anti-mumps IgG-class antibodies in presumptively immune or fully vaccinated HCWs. Although negative results typically prompt revaccination, failure to recognize presumptive immunity in individuals unable to receive live, attenuated vaccines may have employment implications.

Identifiants

pubmed: 32024728
pii: JCM.00136-20
doi: 10.1128/JCM.00136-20
pmc: PMC7098756
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

J Infect Dis. 2009 Feb 15;199(4):552-60
pubmed: 19113988
J Clin Virol. 2015 Aug;69:214-8
pubmed: 26209410
MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45
pubmed: 22108587
Clin Vaccine Immunol. 2017 Jul 5;24(7):
pubmed: 28490424
Clin Infect Dis. 2014 May;58(9):1205-10
pubmed: 24585562
Arch Pediatr Adolesc Med. 2007 Mar;161(3):294-301
pubmed: 17339511
J Infect Dis. 2009 Sep 15;200(6):888-99
pubmed: 19659440
J Infect Dis. 2008 Mar 1;197 Suppl 2:S147-51
pubmed: 18419389
Am J Clin Pathol. 1996 Aug;106(2):170-4
pubmed: 8712168
J Clin Microbiol. 2005 Sep;43(9):4847-51
pubmed: 16145156
J Clin Microbiol. 1995 Apr;33(4):811-5
pubmed: 7790442
J Virol Methods. 2014 May;200:10-4
pubmed: 24486923
Clin Vaccine Immunol. 2011 Sep;18(9):1524-6
pubmed: 21795463
Clin Microbiol Rev. 2016 Jan;29(1):163-74
pubmed: 26607813
J Infect Dis. 2008 Apr 1;197(7):950-6
pubmed: 18419470
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27852634
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34
pubmed: 23760231
J Infect Dis. 1990 Nov;162(5):1036-42
pubmed: 2230231
Pediatr Infect Dis J. 2014 Sep;33(9):992
pubmed: 25361027
MMWR Morb Mortal Wkly Rep. 2007 Jan 12;56(1):1-4
pubmed: 17218934
Clin Vaccine Immunol. 2013 Mar;20(3):443-5
pubmed: 23345583
Pediatrics. 2009 Dec;124(6):1633-41
pubmed: 19933727

Auteurs

Elitza S Theel (ES)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA theel.elitza@mayo.edu.

Marisa Sorenson (M)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Crystal Rahman (C)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Dane Granger (D)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Andrew Vaughn (A)

Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Laura Breeher (L)

Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH